Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau

Journal of Alzheimer's Disease

Volumn 53, Issue 1, 2016, Pages 1-14

  Hensley, Kenneth ^a   Kursula, Petri ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Alzheimer's disease; autophagy; collapsin response mediator protein 2; cyclin dependent kinase; microtubuleassociated protein tau; therapeutic; vesicle transport

Indexed keywords

AMINO ACID; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; HARKOSERIDE; NATURAL PRODUCT; NEUROTROPHIC FACTOR; PHOSPHOTRANSFERASE INHIBITOR; TAU PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN-2; NERVE PROTEIN; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; AUTOPHAGY; CELL MIGRATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOSOME; GENE MUTATION; GENETIC VARIATION; HUMAN; LYSOSOME; MICROTUBULE; MOLECULAR WEIGHT; NERVE DEGENERATION; NEURITE; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TRANSPORT VESICLE; ANIMAL; COMPARATIVE STUDY; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE TISSUE PROTEINS; TAU PROTEINS;

EID: 84976444273     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160076     Document Type: Review

References (99)

1. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986). Microtubule-associated protein tau.Acomponent of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089.
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913-4917.
3. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72, 1858-1862.
4. Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12, 609-622.
5. Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165, 3-12.
6. Iqbal K, Grundke-Iqbal I (2006) Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: A personal historical perspective. J Alzheimers Dis 9(4 Suppl), 219-242.
7. Duyckaerts C, Delatour B, Potier M-C (2009) Classification and basic pathology of Alzheimer's disease. Acta Neuropathol 118, 5-36.
8. Toyn J (2015) What lessons can be learned from failed Alzheimer's disease trials? Expert Rev Clin Pharmacol 8, 267-269.
9. Giacobini E, Gold G (2013) Alzheimer disease therapy: Moving from amyloid-beta to tau. Nat Rev Neurol 9, 677-686.
10. Igbal K, Liu F, Gong CX (2014) Alzheimer's disease therapeutics: Focus on the disease and not just plaques and tangles. Biochem Pharmacol 88, 631-691.
11. Wang Q, Woltier RL, Cimino PJ, Pan C, Montine KS, Zhang J, Montine TF (2005) Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J 19, 869-871.
12. Yoshida H,Watanabe A, Ihara Y (1998) Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer's disease. J Biol Chem 273, 9761-9768.
13. Gu Y, Hamajima N, Ihara Y (2000) Tangle-associated collapsin response mediator protein-2 (CRMP-2) is highly phosphorylated on Thr-509, Ser-518, Ser-522. Biochemistry 39, 4267-4275.
14. Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, Taylor M, LaFrancois J, Gunn-Moore F, Verkhratski A, Oddo S, LaFerla F, Giese KP, Dineley KT, Duff K, Richardson JC, Yan SD, Hanger DP, Allan SM, Sutherland C (2007) Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem 103, 1132-1144.
15. Soutar MP, Thornhill P, Cole AR, Sutherland C (2009) Increased CRMP2 phosphorylation is observed in Alzheimer's disease: Does this tell us anything about disease development? Curr Alzheimer Res 6, 269-278.
16. Takata K, Kitamura Y, Nakata Y, Matsuoka Y, Taomimoto H, Taniguchi T, Shimohama S (2009) Involvement of WAVE1 accumulation in A /APP pathology-dependent tangle modification in Alzheimer's disease. Am J Pathol 175, 17-24.
17. Watamura N, Toba J, Yoshii A, Nikkuni M, Ohshima T (2016) Colocalization of phosphorylated forms ofWAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment. J Neurosci Res 94, 15-26.
18. Hensley K, Venkova K, Christov A, Gunning W, Park J (2011) Collapsin response mediator protein-2: An emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 43, 180-191.
19. Triplett JC, Swomley A, Cai J, Klein JB, Butterfield DA (2016) Quantitative phosphoproteomic analyses of the inferior parietal lobule from three different pathological stages of Alzheimer's disease. J Alzheimers Dis 49, 45-62.
20. Lin PC, Chan PM, Hall C, Manser E (2011) Collapsin response mediator proteins (CRMPs) are a new class of microtubule-associated protein(MAP)that selectively interacts with assembled microtubules via a taxol-sensitive binding interaction. J Biol Chem 286, 41466-41478.
21. Khanna R, Wilson SM, Brittain JM, Weimer J, Sultana R, Butterfield A, Hensley K (2012) Opening Pandora's jar: A primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. Future Neurol 7, 749-771.
22. Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM (1995) Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 376, 509-514.
23. Deo RC, Schmidt EF, Elhabazi A, Togashi H, Burley SK, Strittmatter SM (2004) Structural bases for CRMP function in plexin-dependent semaphorin 3A signaling. EMBO J 23, 9-22.
24. Inagaki N, Chihara K, Arimura N, Menager C, Kawano Y, Matsuo N, Nishimura T, Amano M, Kaibuchi K (2001) CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci 4, 781-782.
25. Cole AR, Knebel A, Morrice NA, Robertson LA, Irving AJ, Connolly CN, Sutherland C (2004) GSK-3 phosphorylation of the Alzheimer epitope within collapsing response mediator proteins regulates axon elongation in primary neurons. J Biol Chem 279, 50176-40180.
26. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K (2005) GSK-3 regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120, 137-149.
27. Uchida Y, Ohshima T, Sasaki Y, Suzuki H, Yanai S, Yamashita N, Nakamura F, Takei K, Ihara Y, Mikoshiba K, Kolattukudy P, Honnorat J, Goshima Y (2005) Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: Implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Genes Cells 10, 165-179.
28. Li T, Hawkes C, Qureshi HY, Kar S, Paudel HK (2006) Cyclin-dependent protein kinase 5 primes microtubuleassociated protein tau site-specifically for glycogen synthase kinase 3-beta. Biochemistry 45, 3134-3145.
29. Quach TT, Duchemin A-M, Rogemond V, Aguera M, Honnorat J, Belin M-F, Kolattukudy PE (2004) Involvement of collapsing response mediator proteins in the neurite extension induced by neurotrophins in dorsal root ganglion neurons. Mol Cell Neurosci 25, 433-443.
30. Arimura N, Inagaki N, Chihara K, Menager C, Nakamura N, Iwamatsu A (2000) Phosphorylation of CRMP-2 by Rho kinase: Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem 275, 23973-23980.
31. Petratos S, Li QX, George AJ, Hou X, Kerr ML, Unabia SE, Hatzinisiriou I, Maksel D, Aguilar MI, SmallDH(2008) The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. Brain 131, 90-108.
32. Amano M, Kaneko T, Maeda A, Nakayama M, Ito M, Yamauchi T, Goto H, FukataY, Oshiro N, Shinohara A, Iwamatsu A, KaibuchiK(2003) Identification of tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase. Neurochem 87, 780-790.
33. Arimura N, Menager C, KawanoY,Yoshimura T, Kawabata S, Hattori A, Fukata Y, Amano M, Goshima Y, Inagaki M, Morone N, Usukura J, Kaibuchi K (2005) Phosphorylation by Rho kinase regulates CRMP-2 activity in growth cones. Mol Cell Biol 25, 9973-9984.
34. Stenmark P, Ogg D, Flodin S, Flores A, Kotenyova T, Nyman T, Nordlund P, Kursula P (2007) The structure of human collapsin response mediator protein 2, a regulator of axonal growth. J Neurochem 101, 906-917.
35. Sengupta A, Novak M, Grundke-Iqbal I, Igbal K (2006) Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett 580, 5925-5933.
36. Panda D, Goode BL, Feinstein SC,Wilson L (1995) Kinetic stabilization of microtubule dynamics at steady state by tau and microtubule-binding domains of tau. Biochemistry 34, 11117-11127.
37. Kadavath H, Hofele RV, Biernat J, Kumar S, Tepper K, Urlaub H, Mandelkow E, Zweckstetter M (2015) Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci U S A 112, 7501-7506.
38. Lykissas MG, Batistatou AK, Konstantinos A, Charalabopoulos KA, Beris AE (2007) The role of neurotrophins in axon guidance, growth and regeneration. Curr Neurovas Res 4, 143-151.
39. Arimura N, Kimura T, Nakamuta S, Taya S, Funahashi Y, Hattori A, Shimada A, Menager C, Kawabata S, Jujii K, Iwamatsu A, Segal RA, Fukuda M, Kaibuchi K (2009) Anterograde transport ofTrkB in axons is mediated by direct interaction with Slp1 and Rab27. Dev Cell 15, 675-686.
40. Rahajeng J, Giridharan SS, Naslavsky N, Caplan S (2010). Collapsin response mediator protein-2 (CRMP2) regulates trafficking by linking endocytic regulatory proteins to dynein motors. J Biol Chem 285, 31918-31922.
41. Kawano Y, Yoshimura T, Tsuboi D, Kawabata S, Kaneko-Kawano T, Shirataki H, Takenawa T, Kaibuchi K (2005) CRMP-2 is involved in kinesin-1-dependent transport of the Swa-1/WAVE1 complex and axon formation. Mol Cell Biol 25, 9920-9935.
42. Pollitt A, Insall RH (2009) WASP and SCAR/WAVE1 proteins: The drivers of actin assembly. J Cell Sci 122, 2575-2578.
43. Arendt T (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118, 167-179.
44. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurology 68, 1501-1508.
45. Nishimura T, Fukata Y, Kato K, Yamaguchi T, Matsuura Y, Kamiguchi H, Kaibuchi K (2003) CRMP-2 regulates polarized Numb-mediated endocytosis for axon growth. Nat Cell Biol 5, 819-826.
46. Kyriazis GA,Wei Z, VandermeyM, Jo DG, Xin O, Mattson MP, Chan SL (2008) Numb endocytic adaptor proteins regulate the transport and processing of the amyloid precursor protein in an isoform-dependent manner: Implications for Alzheimer disease pathogenesis. J Biol Chem 283, 25492-25502.
47. Peraus GC, Masters CL, Beyreuther K (1997) Late compartments of amyloid precursor protein transport in SY5Y cells are involved in beta amyloid secretion. J Neurosci 17, 7714-7724.
48. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing and function. J Biol Chem 283, 29615-29619.
49. Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y,Wuu J, Chao MV, Mufson EJ, Nixon RA, Che S (2010) Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry 68, 885-893.
50. Harris-White ME, Ferbas KG, Johnson MF, Eslami P, Poteshkina A, Venkova K, Christov A, Hensley K (2015) A cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologies. Neurobiol Dis 84, 60-68.
51. Pickford F, Masliah E, Britschgi M, Lucin K, Marasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, Wyss-Coray T (2008) The autophagy-related protein beclin shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 118, 2190-2199.
52. Nixon RA, Yang DS (2011) Autophagy failure in Alzheimer's disease-Locating the primary defect. Neurobiol Dis 43, 38-45.
53. Wolfe DM, Lee JH, Kumar A, Lee S, Orenstein SJ, Nixon RA(2013) Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neurosci 37, 1949-1961.
54. Tramutola A, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, Perluigi M, Butterfield DA (2015) Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): Analysis of brain from subjects with preclinical AD, amnestic mild cognitive impairment and late-stage AD (2015). J Neurochem 133, 739-749.
55. Hensley K, Harris-White ME (2015) Redox regulation of autophagy in healthy brain and neurodegeneration. Neurobiol Dis 84, 50-59.
56. Hensley K, Venkova K, Christov A, Johnson M, Eslami P, Gabbitta SP, Harris-White M (2013) A derivative of the brain metabolite lanthionine ketimine improves cognition and diminishes pathology in the 3xTg-AD mouse model of Alzheimer's disease. J Neuropathol Exp Neurol 72, 955-969.
57. Jiang T, Yu JT, Zhu XC, Tan MS, Wang HF, Cao L, Zhang QQ, Shi JQ, Gao L, Qin H, Zhang YD, Tan L (2014) Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer's disease. Pharmacol Res 81, 54-63.
58. Caccamo A, De Pinto V, Messina A, Branca C, Oddo S (2014) Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological defecits by restoring hippocampal gene expression signature. J Neurosci 34, 7988-7998.
59. Cardenas-Aguayo MC, Gomez-Virgilio L, DeRosa S, Meraz-Rios MA (2014) The role of tau oligomers in the onset of Alzheimer's disease neuropathology. ACS Chem Neurosci 5, 1178-1191.
60. Park SY, Ferreira A (2005) The generation of a 17 kDa neurotoxic fragment: An alternative mechanism by which tau mediates beta amyloid-induced neurodegeneration. J Neurosci 25, 5365-5375.
61. Guzman-Martinez L, Farias GA, Maccioni RB (2013) Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs. Front Neurol 4, 167.
62. Mufson EJ, Ward S, Binder S (2014) Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease. Neurodegener Dis 13, 151-153.
63. Coppola G, Chinnathambi S, Li JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang A, Sears R, Lane JR, Karydas AM, Kennet RO, Biernat J,Want L-S, Cotman CW, DeCarli CS, Levey AI, Ringman JM,Mendez MF, Chui HC, Le Ber I, Brice A, Lupton MK, Preza E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, Lippa CF, Bigio EH, MacKenzi I, Finger E, Kertesz A, Caselli RJ, Gearing M, Juncos JL, Ghetti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, Vonsattel JPG, Zarow C, Beach TG, Albin RL, Lieberman AP, Lee VM, Trojanowski JQ, Van Deerlin VM, Bird TD, Galasko DR, Masliah E, White CL, Troncoso JC, Hannequin D, Boxer AL, Geschwind MD, Kumar S, Mandelkow E-M, Wszolek ZK, Uitti RJ, Dickson Dw, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Alzheimer's Disease Genetics Consortium, Ross OA, Rademakers R, Schellenberg GD, Miller BL, Mandelkow E, Geschwind DH (2012) Evidence for a role of the rare p.A152T variant in MAPT in increasing risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Gen 21, 3500-3512.
64. Lewis J,McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Murphy PM, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25, 402-405.
65. Rohrer J,Warren J (2011) Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 24, 542-540.
66. Liu Y, Pham X, Zhang L, Chen PL, Burzynski G, McGaughey DM, He S, McGrath JA, Wolyniec P, Fallin MD, Pierce MS, McCallion AS, Pulver AE, Avramopoulos D, Valle D (2014) Functional variants in DPYSL2 sequence increase risk of schizophrenia and suggest a link to mTOR signaling. G3 (Bethesda) 5, 61-72.
67. Nakata K, Ujike H, Sakai A, Takaki M, Imamura T, Tanaka Y, Kuroda S (2003) The human dihydropyrimidinase-like protein 2 gene on chromosome 8p21 is associated with paranoid-type schizophrenia. Biol Psychiatry 53, 571-576.
68. Williamson R, van Aalten L, Mann DM, Platt B, Plattner F, Bedford L, Mayer J, Howlett D, Usardi D, Sutherland C, Cole AR (2011) CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases. J Alzheimers Dis 27, 615-625.
69. Morinaka A, Yamada M, Itofusa R, Funato Y, Yoshimura Y, Nakamura F, Yoshimura T, Kaibuchi K, Goshima Y, Hoshino M, Kamiguchi H, Miki H (2011) Thioredoxin mediates oxidation-dependent phosphorylation of CRMP2 and growth cone collapse. Sci Signal 4, ra26.
70. Gellert M, Venz S, Mitlohner J, Cott C, Hanschmann EM, Lillig CH (2013) Identification of a dithiol-disulfide switch in collapsing response mediator protein 2 (CRMP2) that is toggled in a model of neuronal differentiation. J Biol Chem 288, 35117-35125.
71. Zhu JX, Doyle HA, Mamula HJ, Aswad DW(2006) Protein repair in the brain, proteomic analysis of endogenous substrates for protein L-isoaspartyl methyltransferase in mouse brain. J Biol Chem 281, 33802-33813.
72. Majava V, Loytynoja N, Chen W-Q, Lubec G, Kursula P (2008) Crystal and solution structure, stability, and posttranslational modifications of collapsin response mediator protein-2. FEBS J 275, 4583-4596.
73. Reed TT, Pierce WM, Markesbery WR, Butterfield DA (2009) Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res 1274, 66-76.
74. Dustrude ET, Wilson SM, Ju W, Xiao Y, Khanna R (2013) CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking. J Biol Chem 288, 24215-24331.
75. Zhang Z, Ottens AK, Sadasivan S, Kobeissy FH, Fang T, Hayes RL, Wang KK (2007) Calpain-mediated collapsing response mediator protein-1,-2, and-4 proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma 24, 460-472.
76. Kelemen A, Halasz P (2010) Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychiatr Dis Treat 6, 465-471.
77. Wilson SM, Xiong W, Wang Y, Ping X, Head JD, Brittain JM, Gagare PD, Ramachandran PV, Jin X, Khanna R (2012) Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein-2-mediated neurite outgrowth and tubulin polymerization. Neuroscience 17, 451-466.
78. Wilson SM, Moutal A, Melemedjian OK, Wang Y, Ju W, Francois-Moutal L, Khanna M, Khanna R (2014) The functionalized amino acid (S)-lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth. Front Cell Neurosci 8, 196.
79. Wilson SM, Khanna R (2015) Specific binding of lacosamide to collapsing response mediator protein 2 (CRMP2) and direct impairment of its canonical function: Implications for the therapeutic potential of lacosamide. Mol Neurobiol 51, 599-609.
80. Hensley K, Christov A, Kamat S, Zhang XC, Jackson KW, Snow S, Post J (2010) Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures. J Neurosci 30, 2979-2988.
81. Hensley K, Denton TT (2015) Alternative functions of the brain transsulfuration pathway represent an underappreciated aspect of brain redox biochemistry with significant potential for therapeutic manipulation. Free Radic Biol Med 78, 123-134.
82. Hensley K (2010) Emerging biological importance of central nervous system lanthionines. Molecules 15, 5581-5594.
83. Hubbard C, Benda E, HardinT, BaxterT, St. John E, O'Brien S, HensleyK, HolgadoA(2013) Lanthionine ketimine ethyl ester partially rescues neuro-developmental defects in unc-33 (DPYSL2/CRMP2) mutants. J Neurosci Res 91, 1183-1190.
84. Nada SE, Raghava A, Tulsulkar J, Hensley K, Shah, ZA (2012) A derivative of the CRMP2 binding compound lanthionine ketimine provides neuroprotection in a mouse model of cerebral ischemia. Neurochem Int 61, 1357-1363.
85. Dupree JL, Polak PE, Hensley K, Pelligrino D, Feinstein DL (2015) Lanthionine ketimine ester provides benefit in a mouse model of multiple sclerosis. J Neurochem 134, 302-314.
86. Hensley K, Poteshkina A, Johnson MF, Eslami P, Hristov A, Venkova K, Harris-White ME (2015) Autophagy modulation by lanthionine ketimine improves longterm outcome following central fluid percussion injury in the mouse. J Neurotrauma. doi: 10.1089/neu.2015.4196
87. Brittain JM, Piekarz AD, Wang Y, Kondo T, Cummins TR, Khanna R (2009) An atypical role for collapsing response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J Biol Chem 284, 31375-31390.
88. Feldman P, Khanna R (2013) Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interaction with CRMP2 peptides. Neurosci Lett 557(Pt A), 27-36.
89. Kodama Y, Murakumo Y, Ichihara M, Kawai K, Shimono Y, TakahashiM(2004) Induction of CRMP-2 by GDNF and analysis of the CRMP-2 promoter region. Biochem Biophys Res Commun 320, 108-115.
90. Chu CC,Wang JJ, Chen KT, Shieh JP,Wang LK, Shui HA, Ho ST (2010) Neurotrophic effects of tianeptine on hippocampal neurons: A proteomic approach. J Proteome Res 9, 936-944.
91. Liu F, Legastelois R, Morisot N, Ben Hamida S, Ron D (2016) mTORC1-dependent translation of collapsing response mediator protein-2 drives neuroadaptations underlying excessive alcohol-drinking behaviors. Mol Psychiatry. doi: 10.1038/mp.2016.12
92. Caberlotto L, Carboni L, Zanderigo F, Andreetta F, Andreoli M, Gentile G, Razzoli M (2013) Differential effects of glycogen synthase kinase 3 (GSK3) inhibition or selective inhibitors in the central nervous system. Naunyn Schmiedebergs Arch Pharmacol 386, 893-903.
93. Zhang X, Hernandez I, Rei D, Mair W, Laha JK, Cornwell ME, Cuny GD, Tsai LH, Steen JA, Kosik KS (2013) Diaminothiazoles modify tau phosphorylation and improve the tauopathy in mouse models. J Biol Chem 288, 22042-22056.
94. Venkova K, Christov A, Kamaludin Z, Kobalka P, Siddique S, Hensley K (2014) Semaphorin-3A (Sema3A) signaling through neuropilin-1 (NRP1) is an early trigger for distal axonopathy in the SOD1G93A mouse model of familial amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 73, 702-713.
95. Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, Brachmann RK, Patnaik K (2014) A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs 32, 653-660.
96. Kikuchi K, Kishino A, Konishi O, Kumagai K, Hosatani N, Saji I, Nakayama C, Kimura T (2003) In vitro and in vivo characterization of a novel semaphoring 3A inhibitor, SM-216289 or xanthofulvin. J Biol Chem 278, 42985-42991.
97. Kaneko S, Iwanami A, Nakamura M, Kishino A, Kikuchi K, Shibata S, Okano HJ, Ikegami T, Moriya A, Konishi O, Nakayama C, Kumagai K, Kimura T, Sato Y, Goshima Y, Taniguchi M, Ito M, He Z, Toyama Y, Okano H (2006) A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord. Nat Med 12, 1380-1389.
98. Good PF, Alapat D, Hsu A, Chu C, Perl D,Wen X, Burstein DE, Kohtz DS (2004) A role for semaphoring 3A signaling in the degeneration of hippocampal neurons during Alzheimer's disease. J Neurochem 91, 716-736.
99. Jun G, Asai H, Zeldich E, Drapeau E, Chen C, Chung J, Park JH, Kim S, HaroutunianV, Foroud T,Kuwano R, Haines JL, Pericak-VanceMA,Schellenberg GD, Lunetta KL, KimJW, Buxbaum JD, Mayeux R, Ikezu T, Abraham CR, Farrer LA (2014) PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation. Ann Neurol 76, 379-392.